Outlook Therapeutics, Inc. Gains 48.31%
Thu, Jan 02, 2020 at 05:30 PM
Outlook Therapeutics, Inc. (OTLK:NASDAQ) rocketted at $0.88, a gain of 48.3%. On Wed 01 Jan 20, OTLK:NASDAQ hit a New 2-Week Intraday Low of $0.53. The stock got featured on our News Catalysts scanner on Tue 24 Dec 19 at 11:33 AM in the 'BIOTECH' category. From Tue 10 Dec 19, the stock recorded 14.29% Up Days and 33.33% Green Days
About Outlook Therapeutics, Inc. (OTLK:NASDAQ)
Oncobiologics Inc is a clinical stage biopharmaceutical company. It is focused on identifying, developing, manufacturing and commercializing complex mAb therapeutics. The company has introduced BioSymphony Platform to produce high-quality innovative and biosimilar mAb candidates in an efficient and cost-effective manner.
Top 10 Gainers:
- Inpixon (INPX:NASDAQ), 201.83%
- DPW Holdings, Inc. (DPW:NYSEMKT), 101.65%
- Synthesis Energy Systems, Inc. (SES:NASDAQ), 100%
- Pulmatrix, Inc. (PULM:NASDAQ), 88.37%
- Outlook Therapeutics, Inc. (OTLK:NASDAQ), 48.31%
- Trillium Therapeutics Inc. (TRIL:NASDAQ), 44.66%
- Cassava Sciences, Inc. (SAVA:NASDAQ), 38.46%
- ToughBuilt Industries, Inc. (TBLT:NASDAQ), 37.45%
- Sophiris Bio, Inc. (SPHS:NASDAQ), 35.05%
- Aethlon Medical, Inc. (AEMD:NASDAQ), 29.8%